← Leaderboards
William M Ridgway
Va Northern California Health Care Sys
$7,112,330
Attributed
$12,878,822
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,878,822 · 5
VA$0 · 2
By mechanism
R01$12,444,259 · 4
R21$434,563 · 1
I01$0 · 2
Top collaborators
- Yi-Guang Chen10 shared
- Merrill E Gershwin8 shared
- Andrew B Herr3 shared
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingT-LymphocyteImmunePathway InteractionsCellsPathogenicityIn VivoInflammationAutoimmunityPublishingMouse ModelSignal TransductionProductionIn VitroCytokineGrantInflammatoryRegulatory T-LymphocyteInsulin-Dependent Diabetes MellitusInbred Nod MiceAutoimmune ProcessCd8b1 GeneAntibodiesGenes
Grant awards (37)
Mechanistic and Therapeutic Role of the TLR4 Signaling Pathway in Type 1 Diabetes$679,054
R01 · FY2025 · DK · contact PI
Mechanistic and therapeutic role of the CD137-CD137L axis in Type 1 Diabetes$636,595
R01 · FY2025 · DK
Mechanistic and Therapeutic Role of the TLR4 Signaling Pathway in Type 1 Diabetes$657,760
R01 · FY2024 · DK · contact PI
Mechanistic and therapeutic role of the CD137-CD137L axis in Type 1 Diabetes$611,130
R01 · FY2024 · DK
Mechanistic and Therapeutic Role of the TLR4 Signaling Pathway in Type 1 Diabetes$703,222
R01 · FY2023 · DK · contact PI
Mechanistic and therapeutic role of the CD137-CD137L axis in Type 1 Diabetes$634,906
R01 · FY2023 · DK
Immunogenetic control of autoimmune biliary disease$0
I01 · FY2023 · VA · contact PI
Mechanistic and therapeutic role of the CD137-CD137L axis in Type 1 Diabetes$633,723
R01 · FY2022 · DK
Immunogenetic control of autoimmune biliary disease$0
I01 · FY2022 · VA · contact PI
Mechanistic and therapeutic role of the CD137-CD137L axis in Type 1 Diabetes$642,329
R01 · FY2021 · DK
Mechanistic and Therapeutic Role of the CD137-CD137L Axis in Type 1 Diabetes$482,209
R01 · FY2020 · DK
Immunogenetic control of autoimmune biliary disease$0
I01 · FY2020 · VA · contact PI
Mechanistic and Therapeutic Role of the CD137-CD137L Axis in Type 1 Diabetes$487,598
R01 · FY2019 · DK
Immunogenetic control of autoimmune biliary disease$0
I01 · FY2019 · VA · contact PI
Immunogenetic control of autoimmune biliary disease$0
I01 · FY2019 · VA · contact PI
Mechanistic and Therapeutic Role of the CD137-CD137L Axis in Type 1 Diabetes$492,860
R01 · FY2018 · DK
Immunogenetic control of autoimmune biliary disease$0
I01 · FY2018 · VA · contact PI
dnTGF Beta RII Mice and PBC$502,486
R01 · FY2017 · DK
Mechanistic and Therapeutic Role of the CD137-CD137L Axis in Type 1 Diabetes$497,993
R01 · FY2017 · DK
Mechanistic and Therapeutic Role of the CD137-CD137L Axis in Type 1 Diabetes$530,508
R01 · FY2016 · DK
dnTGF Beta RII Mice and PBC$502,072
R01 · FY2016 · DK
Mechanism of restored immune tolerance in anti-TLR4 antibody reversal of NOD T1D$197,500
R21 · FY2016 · AI · contact PI
dnTGF Beta RII Mice and PBC$502,329
R01 · FY2015 · DK
Mechanism of restored immune tolerance in anti-TLR4 antibody reversal of NOD T1D$237,063
R21 · FY2015 · AI · contact PI
Immunogenetic Control of Autoimmune Liver Disease$0
I01 · FY2015 · VA · contact PI
dnTGF Beta RII Mice and PBC$516,307
R01 · FY2014 · DK
Immunogenetic Control of Autoimmune Liver Disease$0
I01 · FY2014 · VA · contact PI
dnTGF Beta RII Mice and PBC$410,254
R01 · FY2013 · DK
Immunogenetic Control of Autoimmune Liver Disease$0
I01 · FY2013 · VA · contact PI
dnTGF Beta RII Mice and PBC$425,135
R01 · FY2012 · DK
Immunogenetic Control of Autoimmune Liver Disease$0
I01 · FY2012 · VA · contact PI
dnTGF Beta RII Mice and PBC$433,422
R01 · FY2011 · DK
dnTGF Beta RII Mice and PBC$551,093
R01 · FY2010 · DK
Mechanism of NOD.IDD3/10/17/18/9(LD) Liver Disease$213,176
R01 · FY2005 · DK
Mechanism of NOD.IDD3/10/17/18/9(LD) Liver Disease$213,671
R01 · FY2004 · DK
Mechanism of NOD.IDD3/10/17/18/9(LD) Liver Disease$214,761
R01 · FY2003 · DK
Mechanism of NOD.IDD3/10/17/18/9(LD) Liver Disease$269,666
R01 · FY2002 · DK